Page 221 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Patients (N) 8
30
20
Reason not to perform DPYD genotyping
5-FU or CAP therapy started just prior to the start date of 15 April 2013
5-FU or CAP was used before April 2013 without problems and would start again after 15 April 2013
No medical dossier at the Medical Oncology department was found, therefore the patient was not treated at the LUMC
Evaluating the implementation of prospective DPYD genotyping
Table 2. Excluded patients
Patients (N=60) with legitimate reasons not to screen were excluded from analysis.
These dossiers were fake patients used for education purposes
2
Abbreviations: 5-FU: 5-fluorouracil; CAP: capecitabine.
Intention to start
Genotyping
Percentage
110. 0 100. 0 90. 0 80. 0 70. 0 60. 0 50. 0 40. 0 30. 0 20. 0 10. 0
40 35 30 25 20 15 10 5
0.0 0
Figure 2. Proportion of eligible patients that were genotyped
The figure shows the eligible patients for evaluation per month in actual patient numbers. If the intention to treat with 5-FU or capecitabine was present, patients were eligible. Also the actual patient numbers of the genotyped patients per month are shown and the calculated percentage which represents the clinical acceptance, or how well implemented the prospective DPYD screening is.
219
8
Percentage
Patients (n)
April2013 May 2013
June 2013 July 2013
August 2013 September 2013
October2013 November 2013
Decemb er 201 3 January 2014
February 2014 March 2014
April2014 May 2014
June 2014 July 2014
August 2014 September 2014
October2014 November 2014
Decemb er 201 4